Several international studies, such as Satoh et al. (2013) and Shinohara et al. (2010), have reported that plasma CyPA levels are significantly elevated in patients with acute coronary syndromes compared to controls and may serve as a novel biomarker of coronary artery disease activity (5, 25). This evidence concerns the gene PPIA and acute coronary syndrome.